IBRX Immunitybio Inc
Company Analysis
Latest News
🔴 Immunitybio is trading at 10.3% down amid broader market and biotech declines
Immunitybio is trading 10.3% down at $8.01 amid steep declines across the broader market and biotech, with no confirmed company announcement directly...
🔴 Immunitybio is trading 4.4% down on November 5, 2026 with no confirmed company explanation
Immunitybio is trading at $8.54, down 4.37%, with no confirmed November 5 company announcement directly explaining the decline. - Third-quarter results were...
🟢 Immunitybio is trading 5% up on November 4, 2026, amid biotech sector strength
Immunitybio is trading at $8.72, up 5.25%, amid biotech sector strength. - XBI was up 2.13%, while major U.S. indexes also rose sharply. - On November 4,...
🟢 Immunitybio is trading 5% up
Immunitybio is trading at $8.35 (+5.03%), with no confirmed company announcement explaining the move. - A November 3 report said founder Patrick Soon-Shiong’s...
🔴 Immunitybio is trading 4.04% down today as biotech ETF XBI falls 2.39%
Immunitybio is trading 4.04% down at $7.96 as broad biotech weakness weighs on shares. - The sector ETF XBI is down 2.39%, and the provided market data also...
Immunitybio Inc Q3 2026 Earnings Preview: What Analysts Expect on November 03, 2026
Analysts expect ImmunityBio to report Q3 2026 revenue of $59.23 million and a consensus EPS of -$0.07, with shares currently trading at $8.53 against an...
🔴 Immunitybio is trading 6.24% down today with no clear company-specific catalyst
Immunitybio is trading 6.24% down at $8.28, alongside broad market weakness; no clear company-specific announcement explaining the October 30 move surfaced. -...
🟢 Immunitybio is trading 10.3% up today amid biotech sector gains; no company catalyst confirmed
Immunitybio is trading at $8.62, up +10.31%, with biotech strength providing context; no confirmed company-specific catalyst was identified for October 27. -...
🟢 Immunitybio is trading 4.3% up — no confirmed catalyst
Immunitybio is trading at $8.14 (+4.29%), with no confirmed catalyst for the move. - The latest listed company release was an October 21 trial database-lock...
🔴 Immunitybio is trading 5% down
Immunitybio is trading 5.23% down at $7.79 on October 26, 2026; no clear company-specific catalyst was identified. - The latest company announcement was the...
🔴 Immunitybio is trading 4.8% down today with no clear company-specific catalyst
Immunitybio is trading at $8.22, down -4.80%, with no clear company-specific catalyst identified. - The recent ANKTIVA approval expansion and bladder-cancer...
🔴 Immunitybio is trading 4.73% down today — no clear catalyst identified
Immunitybio is trading 4.73% down at $8.36 on October 21, 2026, with no clear catalyst identified. - The company completed the database lock for its...
ImmunityBio Locks Bladder Cancer Trial Database Ahead of 2026 Results
ImmunityBio completed the database lock for its registrational trial of ANKTIVA plus BCG in 366 patients with BCG-naïve non-muscle invasive bladder cancer...
🟢 Immunitybio is trading 4.51% up today with biotech-sector support; no direct catalyst identified
Immunitybio is trading at $8.80, up 4.51%, with biotech-sector gains offering support; no direct cause for the session’s move has been established. - The...
ImmunityBio Reports Strong ANKTIVA Results, Amid Mounting Legal Investigations
ImmunityBio announced long-term results from its Phase 2/3 QUILT-3.032 clinical trial for ANKTIVA. The study combined ANKTIVA with Bacillus Calmette-Guerin...
ImmunityBio Reports 71% Complete Response Rate in Bladder Cancer Trial
ImmunityBio announced the publication in the Journal of Urology of long-term results from its Phase 2/3 trial of ANKTIVA plus BCG in patients with a type of...
🔴 Immunitybio is trading 5% down today amid biotech sector weakness
Immunitybio is trading 4.8% lower at $9.52, with biotech-sector weakness the clearest supporting context but no confirmed company-specific negative...
🟢 Immunitybio is trading 5.65% up today after FDA expanded ANKTIVA approval for bladder cancer treatment
Immunitybio is trading at $10.47 (+5.65%) after the FDA expanded ANKTIVA’s approval to cover BCG-unresponsive bladder cancer with papillary-only tumors. • The...
IBRX Receives Expanded FDA Approval for ANKTIVA in Bladder Cancer Treatment
ImmunityBio announced on October 14, 2026, that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for its drug, ANKTIVA®, used...
🟢 Immunitybio is trading 5% up today after FDA expands Anktiva for papillary-only bladder cancer
Immunitybio is trading 5.05% up at $10.29 alongside the FDA’s October 14, 2026 expansion of Anktiva’s approval. - The significant company-specific milestone...